Cannabis Law Report

OCTOBER 6, 2021

Flora will conduct thorough due diligence and honor the traditional FDA and NHS route in scientific processes to ensure consistency, quality, and delivery of cannabinoids for specific disease conditions, backed by data, with an initial focus on fibromyalgia, brain health, pain, and related research.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Cannabis Law Report

SEPTEMBER 14, 2021

A lack of consumer trust, transparency and scientific rigor has hampered the CBD and cannabinoid industry from reaching its growth potential for far too long”. Step four: Brands select packaging, labels and other physical concepts for the selected product in a fully customizable experience.

Extraction 52

Extraction Research and Development Clinical Trials CBD 52

Cannabis Law Report

APRIL 10, 2019

MP Philippa Whitford (representing Central Ayrshire ), a doctor, called for more support for clinical trials so that doctors will be more willing to prescribe medical cannabis products: “That is quite scary for doctors, particularly as if it is an unlicensed drug, they have to sign a form to say that they accept personal liability.

Clinical Trials 51

Clinical Trials Epilepsy Medicine Research and Development 51

The Cannigma

FEBRUARY 11, 2021

Listen & Subscribe: When Mara Gordon started using medical cannabis there wasn’t any lab testing — or any way to know how much of each cannabinoid or terpene was in a given strain. All of that data is packaged into software doctors can use to manage their patients’ medical marijuana treatment. “I I know how to collect data.

Wellness and Beauty 125

Wellness and Beauty Data Patients Medicine 125

Cannabis Law Report

OCTOBER 17, 2019

Selinger cites software, point-of-sale systems, and packaging as areas that are thriving in the state. THC is just one of the cannabinoids in the Cannabis sativa L. The other major cannabinoid of particular interest commercially is cannabidiol (CBD). Colorado has legalized both recreational and medical use of cannabis.

Law 40

Law Seed-To-Sale Hemp Recreational 40

Cannabis Law Report

DECEMBER 30, 2019

For the first time, the FY 2020 Appropriations package contained this protection for 47 states within the base language of the text. Included in the final FY 2020 spending package). Specifically, it expands the pool of patients eligible for cannabis therapy to include those with chronic pain, menstrual cramps, and epilepsy.

Legislation 59

Legislation Patients Access Banking 59